As in other settings, anti-tumour T cell responses are initiated when conventional dendritic cells (cDC) take up tumour antigens in the context of damage associated molecular patterns, mature and migrate to the tumour draining lymph node (tdLN) where they present antigen in the context of MHC to antigen specific T cells [21–23]. The gene discussed is HLA-C; the disease is neoplasm.